Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1615)	9/25/2007 12:13:48 PM
From: Jibacoa	Respond to of 3722

CBMX Was up 12.35% earlier, but is up only 9.8% at present.<g> bigcharts.marketwatch.com It had an announcement on its HemeScan CombiMatrix Molecular Diagnostics Launches HemeScan MDS for the Management and Diagnosis of Myelodysplastic Syndromes Tuesday September 25, 9:00 am ET MUKILTEO, Wash., Sept. 25, 2007 (PRIME NEWSWIRE) -- CombiMatrix Corporation (NasdaqCM:CBMX - News) announced today that its subsidiary, CombiMatrix Molecular Diagnostics (or ``CMDX''), has completed the clinical validation of the third of its HemeScan(tm) suite of Bacterial Artificial Chromosome (or ``BAC'') Comparative Genomic Hybridization (or ``CGH'') array-based tests. HemeScan(tm) MDS (myelodysplastic syndromes) is designed to detect clonal prognostic markers in bone marrow aspirates from patients with refractory anemia combining diagnosis of pre-leukemia with individualized risk stratification and treatment planning. It is now available to the clinical community through both routine clinical sample processing as well as through CMDX's innovative Technical Only Program for reference laboratories. The HemeScan tests are the industry's first clinically validated cancer diagnostics based on BAC array CGH technology. Several thousand cases of MDS, a group of diseases caused by abnormal bone marrow cells, are diagnosed each year in the United States. Most cases occur in older adults, but MDS can be seen in people of all ages including children who have received chemotherapy or radiation therapy for other malignancies. Affected individuals are at risk for bleeding and infection due to bone marrow failure and approximately 40% of MDS patients will transform to acute leukemia within a few months to years after diagnosis. To identify those at high risk for leukemic transformation, patients are given an individualized prognosis based on the International Prognostic Scoring System (or ``IPSS''). The IPSS score risk-stratifies patients into ``good'', ``intermediate'' and ``poor'' categories based on blood cell counts and chromosome abnormalities. HemeScan(tm) MDS is designed to detect chromosome imbalances included in the IPSS scoring system while simultaneously giving clinicians a genome-wide analysis of the abnormal cells. HemeScan is designed to quickly give clinicians an overview of the genome and identify the specific chromosome abnormalities used for grouping patients into specific IPSS prognostic groups'', said Dr. Shelly Gunn, Medical Director of CMDX. Snip Bernard